Isomorphic Labs

Isomorphic Labs Limited is a London-based drug discovery company, which uses artificial intelligence for drug discovery. Isomorphic Labs was founded by Demis Hassabis. The company was incorporated on February 4, 2021 and announced on November 5, 2021. It was established under Alphabet Inc. as a spin-off from its AI research lab DeepMind. Hassabis is the CEO and founder.

Isomorphic Labs Limited
Company typeSubsidiary
IndustryDrug discovery
Founded1 November 2021 
FounderDemis Hassabis
HeadquartersLondon
Key people
  • Demis Hassabis (CEO)
  • Pamela Carroll (COO)
  • Miles Congreve (CSO)
  • Max Jaderberg (Chief AI Officer)
ParentAlphabet Inc.
Websiteisomorphiclabs.com

The company draws upon DeepMind's AlphaFold 2 technology, which can be used to predict protein structures in the human body with high accuracy, allowing its researchers to find new target pathways for drug delivery.

In December 2022, Isomorphic Labs announced its second office location in Lausanne, Switzerland.

In January 2024, Isomorphic Labs partnered with Novartis AG and Eli Lilly & Company to work together on AI drug discovery and research.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.